Login Register Cart 0
Generic placeholder image

Current Analytical Chemistry

Editor-in-Chief

ISSN (Print): 1573-4110
ISSN (Online): 1875-6727

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of a New, Fully Validated LC-MS/MS Method for the Analysis of Flibanserin in Pharmaceutical Preparations and Comparison of the Chromatographic Performance with Six Stationary Phase Types

Author(s): Aysun Geven, Saniye Özcan, Serkan Levent and Nafiz Öncü Can*

Volume 19, Issue 7, 2023

Published on: 04 September, 2023

Page: [541 - 549] Pages: 9

DOI: 10.2174/1573411019666230726121218

Price: $65

Abstract

Background: Initially synthesized as an antidepressant and potentially rapid onset of action, flibanserin (FLB) was approved by the Food and Drug Administration (FDA) in August 2015 with a warning to dispense the drug through a dedicated risk management program, despite the removal of HSDD from the DSM-5TM. The drug is the first noteworthy FDA-approved drug for treating premenopausal women with acquired, generalized HSDD.

Objective: In literature, studies are plasma analyses or metabolite determinations to meet pharmacokinetic analyses and some analytical targets. For this reason, in this thesis, a new method has been developed for analysing FLB from pharmaceutical preparations, which is our target, providing all optimization conditions and method validity parameters.

Method: The chromatographic separation was also investigated using Chromolith® and Ascentis® Express models with a total of six stationary phases. The mobile phase mixture was acetonitrile:ammonium formate (0.020 M, pH 6.0) and was used at the ratio (60:40, v/v). The optimum column temperature was chosen as 40.0±0.1°C, and the autosampler thermostat temperature was chosen as 15±0.1°C. The sample injection volume is optimized to be 1 μL.

Results: The developed method is linear in the range of 2.63–105.0 ng/mL, and the regression coefficient is 0.999 intraday and 0.986 interday. In the method, LOD and LOQ were obtained as 128 pg/mL and 384 pg/mL, respectively. In addition, the ANOVA P values were calculated as 0.586 and 0.914, respectively, in the validation studies conducted intraday and interday.

Conclusion: FLB chromatographic behaviors were studied and compared in detail with six different stationary phases. The developed method was fully validated according to the ICH Q2 (R1) guideline, and its pseudo-pharmaceutical formulation was analyzed.

« Previous Next »
Graphical Abstract

[1]
Basson, R. The female sexual response: A different model. J. Sex Marital Ther., 2000, 26(1), 51-65.
[http://dx.doi.org/10.1080/009262300278641] [PMID: 10693116]
[2]
Puppo, G.; Puppo, V. US Food and Drug Administration approval of Addyi (flibanserin) for treatment of hypoactive sexual desire disorder. Eur. Urol., 2016, 69(2), 379-380.
[http://dx.doi.org/10.1016/j.eururo.2015.09.050] [PMID: 26455357]
[3]
Fisher, W.A.; Pyke, R.E. Flibanserin efficacy and safety in premenopausal women with generalized acquired hypoactive sexual desire disorder. Sex. Med. Rev., 2017, 5(4), 445-460.
[http://dx.doi.org/10.1016/j.sxmr.2017.05.003] [PMID: 28666836]
[4]
Arnow, B.A.; Millheiser, L.; Garrett, A.; Lake Polan, M.; Glover, G.H.; Hill, K.R.; Lightbody, A.; Watson, C.; Banner, L.; Smart, T.; Buchanan, T.; Desmond, J.E. Women with hypoactive sexual desire disorder compared to normal females: A functional magnetic resonance imaging study. Neuroscience, 2009, 158(2), 484-502.
[http://dx.doi.org/10.1016/j.neuroscience.2008.09.044] [PMID: 18976696]
[5]
Woodard, T.L.; Nowak, N.T.; Balon, R.; Tancer, M.; Diamond, M.P. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: A cross-sectional pilot study. Fertil. Steril., 2013, 100(4), 1068-1076.
[http://dx.doi.org/10.1016/j.fertnstert.2013.05.041]
[6]
Cooper, E.B.; McBride, J.; Levine, S. Does flibanserin have a future? Psychiat. Times, 2016, 33(1) Available from:https://www.psychiatrictimes.com/view/does-flibanserin-have-future
[7]
Sieger, P.; Cui, Y.; Scheuerer, S. pH-dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability. Eur. J. Pharm. Sci., 2017, 105, 82-90.
[http://dx.doi.org/10.1016/j.ejps.2017.04.016] [PMID: 28478135]
[8]
Flibanserin CID=6918248., 2017. Available from:https://pubchem.ncbi.nlm.nih.gov/compound/Flibanserin#section=Related-Records(accessed 10 July)
[9]
Poplawska, M.; Blazewicz, A.; Zolek, P.; Fijalek, Z. Determination of flibanserin and tadalafil in supplements for women sexual desire enhancement using high-performance liquid chromatography with tandem mass spectrometer, diode array detector and charged aerosol detector. J. Pharm. Biomed. Anal., 2014, 94, 45-53.
[http://dx.doi.org/10.1016/j.jpba.2014.01.021] [PMID: 24531007]
[10]
Sultan, M.A.; El-Eryan, R.T.; Attia, A.K.; Eissa, M.J. Development and validation of liquid chromatography–electrospray–tandem mass spectrometry method for determination of flibanserin in human plasma: Application to pharmacokinetic study on healthy female volunteers. Biomed. Chromatogr., 2019, 33(8), e4545.
[http://dx.doi.org/10.1002/bmc.4545] [PMID: 30937940]
[11]
He, L.; You, W.; Wang, S.; Jiang, T.; Chen, C. A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: Application to a pharmacokinetic study. BMC Chem., 2019, 13(1), 111.
[http://dx.doi.org/10.1186/s13065-019-0620-9] [PMID: 31463480]
[12]
Trocóniz, I.F.; Boland, K.; Staab, A. Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers. Pharm. Res., 2012, 29(6), 1518-1529.
[http://dx.doi.org/10.1007/s11095-011-0648-6] [PMID: 22219166]
[13]
Iqbal, M.; Ezzeldin, E.; Rezk, N.L.; Bajrai, A.A.; Al-Rashood, K.A. A validated UPLC–MS/MS method for flibanserin in plasma and its pharmacokinetic interaction with bosentan in rats. Bioanalysis, 2018, 10(14), 1087-1097.
[http://dx.doi.org/10.4155/bio-2018-0065] [PMID: 29692180]
[14]
Sharma, M.K.; Rathod, R.; Sengupta, P. Mass spectrometry-based rapid quantitative bioanalysis of flibanserin: Pharmacokinetic and brain tissue distribution study in female rats. J. Anal. Toxicol., 2020, 44(6), 559-569.
[15]
Kowmudi, G.; Anbu, K.; Prakash, M.U.; Rajan, P.D.; Ramalingam, P.; Krishnaveni, N. A novel LC-ESI-MS/MS method for the quantification of flibanserin in bulk and pharmaceutical formulations. royal society of chemistry In: Conference on Drug Design and Discovery Technologies, The Royal Society of Chemistry.2019, 355, pp. 330-339.
[http://dx.doi.org/10.1039/9781839160783-00330]
[16]
Bao, Q.; Zhao, H.; Han, S.; Zhang, C.; Hasi, W. Surface-enhanced Raman spectroscopy for rapid identification and quantification of Flibanserin in different kinds of wine. Anal. Methods, 2020, 12(23), 3025-3031.
[http://dx.doi.org/10.1039/D0AY00741B] [PMID: 32930162]
[17]
Brickl, R-S.; Boni, J.; Wagner, K.G. Formulations of Flibanserin. 2009100886:A3, 2009.
[18]
Smith, J.S.; McLafferty, D.F.W. Evidence for a stepwise mechanism for the γ-hydrogen rearrangement. Org. Mass Spectrom., 1971, 5(4), 483-485.
[http://dx.doi.org/10.1002/oms.1210050415]
[19]
Demarque, D.P.; Crotti, A.E.M.; Vessecchi, R.; Lopes, J.L.C.; Lopes, N.P. Fragmentation reactions using electrospray ionization mass spectrometry: An important tool for the structural elucidation and characterization of synthetic and natural products. Nat. Prod. Rep., 2016, 33(3), 432-455.
[http://dx.doi.org/10.1039/C5NP00073D] [PMID: 26673733]
[20]
Jogpethe, A.; Jadav, T.; Rajput, N.; Sahu, A.K.; Tekade, R.K.; Sengupta, P. Critical strategies to pinpoint carryover problems in liquid chromatography-mass spectrometry: A systematic direction for their origin identification and mitigation. Microchem. J., 2022, 179, 107464.
[21]
Tripathy, H.K.; Kiran, V.; Zakkula, A. A B, V.; Bestha, R.M.; Dittakavi, S.; Mullangi, R. Validated LC-MS/MS method for the determination of copanlisib in mouse dried blood spots. Biomed. Chromatogr., 2023, 37(2), e5548.
[http://dx.doi.org/10.1002/bmc.5548] [PMID: 36385469]
[22]
ICH Expert Working Group Q2 (R1) Validation of analytical procedures: Text and methodology. ICH Harmonised Tripartite Guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Chicago2005.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy